Skip to main content
رجوع
HCM logo

HUTCHMED (China) Limited

جودة البيانات: 100%
HCM
NASDAQ Healthcare Drug Manufacturers - Specialty & Generic
KWD 14.12
▲ KWD 0.12 (0.86%)
القيمة السوقية: 2.55B
مُدرج أيضًا باسم HMDCF OTC
نطاق اليوم
KWD 13.84 KWD 14.12
نطاق 52 أسبوعًا
KWD 11.51 KWD 19.50
حجم التداول
16,136
متوسط 50 يوم / 200 يوم
KWD 14.74 / KWD 15.33
الإغلاق السابق
KWD 14.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس السهم وسيط القطاع
P/E 5.6 0.3
P/B 2.1 2.9
ROE % 45.9 3.7
Net Margin % 83.3 3.8
Rev Growth 5Y % 11.5 10.0
D/E 0.1 0.2

السعر المستهدف للمحللين

Hold
KWD 17.500 +23.9%
مكرر الربحية المستقبلي
44.1
ربحية السهم المستقبلية
KWD 0.317
نمو ربحية السهم (تقدير)
+0.0%
الإيرادات المقدّرة
640 M

تقديرات الأرباح

الفترة تقدير ربحية السهم تقدير الإيرادات المحللون
FY2030 KWD 1.170
KWD 1.087 – KWD 1.352
1.2 B 1
FY2029 KWD 0.885
KWD 0.822 – KWD 1.022
1.1 B 1
FY2028 KWD 0.599
KWD 0.557 – KWD 0.692
840 M 1

النقاط الرئيسية

Revenue grew 11.48% annually over 5 years — strong growth
Earnings grew 1114.23% over the past year
ROE of 45.86% indicates high profitability
Net margin of 83.30% shows strong profitability
Debt/Equity of 0.08 — conservative balance sheet
Negative free cash flow of -79.01M

النمو

Revenue Growth (5Y)
11.48%
Revenue (1Y)-12.73%
Earnings (1Y)1114.23%
FCF Growth (3Y)N/A

الجودة

Return on Equity
45.86%
ROIC-3.07%
Net Margin83.30%
Op. Margin-9.95%

الأمان

Debt / Equity
0.08
Current Ratio4.96
Interest Coverage-19.05

التقييم

P/E Ratio
5.57
P/B Ratio2.06
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -12.73% Revenue Growth (3Y) -18.99%
Earnings Growth (1Y) 1114.23% Earnings Growth (3Y) 113.21%
Revenue Growth (5Y) 11.48% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 549.96M Net Income (TTM) 458.12M
ROE 45.86% ROA 26.13%
Gross Margin 38.68% Operating Margin -9.95%
Net Margin 83.30% Free Cash Flow (TTM) -79.01M
ROIC -3.07% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.08 Current Ratio 4.96
Interest Coverage -19.05 Dividend Yield 0.00%
Valuation
P/E Ratio 5.57 P/B Ratio 2.06
P/S Ratio 4.64 PEG Ratio 0.00
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 2.55B Enterprise Value 2.58B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 549.96M 630.20M 838.00M 426.41M 356.13M
Net Income 458.12M 37.73M 100.78M -360.84M -194.65M
EPS (Diluted) 2.60 0.22 0.60 -2.15 -1.25
Gross Profit 212.72M 281.32M 453.55M 115.31M 97.89M
Operating Income -54.73M -43.71M 18.38M -409.77M -344.29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 1.75B 1.27B 1.28B 1.03B 1.37B
Total Liabilities 501.84M 502.34M 536.39M 392.58M 333.15M
Shareholders' Equity 1.24B 759.93M 730.54M 610.37M 986.89M
Total Debt 97.89M 89.82M 86.13M 27.01M 38.98M
Cash & Equivalents 71.33M 153.96M 283.59M 313.28M 377.54M
Current Assets 1.57B 1.07B 1.10B 839.89M 1.21B
Current Liabilities 315.78M 376.56M 403.03M 353.90M 311.66M

درجات الاستراتيجيات

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches

النشاط الأخير

دخل Contrarian Investing (David Dreman)
Mar 24, 2026